Patients with triple-negative breast cancer do not benefit from the addition of atezolizumab to their post-surgery chemotherapy treatment, according to the results of a large phase 3 clinical trial presented at the 14th European ...
Mar 19, 2024
0
1
The immunotherapy agent atezolizumab induces sustained responses in about one-third of patients with advanced alveolar soft part sarcoma (ASPS), according to a study published in the Sept. 7 issue of the New England Journal ...
Sep 8, 2023
0
26
For patients with non-small cell lung cancer (NSCLC) ineligible for platinum-based chemotherapy, first-line atezolizumab monotherapy is associated with improved overall survival compared to single-agent chemotherapy, according ...
Aug 15, 2023
0
4
A global study, led by UCL and UCLH, has shown that the cancer immunotherapy atezolizumab significantly improved the overall survival of advanced stage non-small cell lung cancer patients who were not able to be treated with ...
Jul 6, 2023
1
45
Locally advanced cervical cancer remains an area of high therapeutic need, with recent trials failing to demonstrate evidence of benefit from adjuvant chemotherapy or immune checkpoint blockade administered concurrent with ...
Mar 27, 2023
0
8
A clinical trial led by the National Cancer Institute (NCI), part of the National Institutes of Health, has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS). The immunotherapy drug ...
Dec 28, 2022
0
44
A new research paper titled "Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients" has been published in Oncotarget.
Dec 22, 2022
0
26
Updated toxicity data from the ongoing SWOG/NRG 1806 clinical trial, which tests combining chemoradiation therapy with immunotherapy in patients with localized muscle-invasive bladder cancer, reveal no significant safety ...
Oct 25, 2022
0
9
An interim analysis of overall survival data from the IMpower010 trial showed an overall survival trend in favor of atezolizumab in the PD-L1 TC > 1% stage II-IIIA population (OS HR, 0.71 [95% CI: 0.49, 1.03]), but not in ...
Aug 8, 2022
0
17
Researchers who treated a group of post-surgery bladder cancer patients with the immunotherapy drug atezolizumab have found that patients whose blood contained circulating tumor DNA (ctDNA), responded very well to the treatment.
Jul 4, 2022
0
7
